drug_type
RELEVANT_DRUG
intervention_type
CAR T-cell therapy
drug_description
Autologous, gene-modified BCMA-directed CAR T-cell therapy; engineered T cells express an anti-BCMA CAR with 4-1BB costimulatory and CD3ΞΆ signaling domains to induce activation, proliferation, cytokine release, and cytotoxic killing of myeloma cells.
nci_thesaurus_concept_id
C117729
nci_thesaurus_preferred_term
Idecabtagene Vicleucel
nci_thesaurus_definition
A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.
drug_mesh_term
idecabtagene vicleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express a BCMA-directed chimeric antigen receptor with CD3zeta activation and 4-1BB costimulatory domains. CAR engagement of BCMA on malignant plasma cells triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA-expressing tumor cells.
drug_name
Idecabtagene vicleucel
nct_id_drug_ref
NCT06698887